HC Wainwright Issues Positive Forecast for Personalis (NASDAQ:PSNL) Stock Price

Personalis (NASDAQ:PSNLFree Report) had its target price lifted by HC Wainwright from $9.00 to $11.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $7.25 target price on shares of Personalis in a research report on Friday.

Get Our Latest Research Report on Personalis

Personalis Stock Up 9.3 %

Shares of Personalis stock opened at $5.75 on Friday. Personalis has a fifty-two week low of $1.12 and a fifty-two week high of $7.20. The business’s fifty day moving average is $4.37 and its two-hundred day moving average is $3.89. The firm has a market cap of $406.23 million, a PE ratio of -3.42 and a beta of 1.88.

Personalis (NASDAQ:PSNLGet Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. During the same quarter in the previous year, the company posted ($0.51) earnings per share. Equities research analysts anticipate that Personalis will post -1.41 EPS for the current year.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. ARK Investment Management LLC grew its holdings in shares of Personalis by 4.9% during the 2nd quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company’s stock worth $7,443,000 after purchasing an additional 296,413 shares during the period. Acadian Asset Management LLC lifted its position in Personalis by 6.7% during the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock valued at $1,237,000 after buying an additional 66,128 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after buying an additional 4,504 shares during the period. nVerses Capital LLC acquired a new stake in shares of Personalis in the third quarter worth $40,000. Finally, International Assets Investment Management LLC increased its position in shares of Personalis by 438.0% in the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after acquiring an additional 17,082 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

(Get Free Report)

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

Featured Articles

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.